onc206
Targeting dopamine receptor D2 by imipridone suppresses uterine serous cancer malignant phenotype
Cancers (Basel). 2020 PMID: 32867127
Chimerix is now part of Jazz Pharmaceuticals. Learn more at www.jazzpharma.com
Publications
onc201
Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors
Neuro Oncol. 2021 PMID: 32830856
imipridones
Metabolic reprogramming by dual AKT/ERK inhibition through imipridones elicits unique vulnerabilities in glioblastoma
Clin Cancer Res. 2018 PMID: 30037819
onc201
A Bayesian machine learning approach for drug target identification using diverse data types
Nat Commun. 2019 PMID: 31745082
onc201
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients
Neuro Oncol. 2020 PMID: 31702782
onc201
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
J Neurooncol. 2019 PMID: 31456142
imipridones
Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules
ACR Annual Meeting 2019
onc201
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
J Immunother Cancer. 2019 PMID: 31118108
imipridones
Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality
Cancer Cell 2019 PMID: 31056398
onc212
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
Leukemia. 2019 PMID: 31127149
